Two Sigma Investments LP Has $643,000 Holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Two Sigma Investments LP lifted its stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 18.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 46,269 shares of the company’s stock after buying an additional 7,093 shares during the quarter. Two Sigma Investments LP owned about 0.09% of Tyra Biosciences worth $643,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Rhumbline Advisers grew its position in shares of Tyra Biosciences by 4.1% during the 4th quarter. Rhumbline Advisers now owns 26,202 shares of the company’s stock worth $364,000 after buying an additional 1,027 shares during the period. BNP Paribas Financial Markets acquired a new stake in Tyra Biosciences in the 4th quarter valued at $60,000. RA Capital Management L.P. grew its position in Tyra Biosciences by 2.1% in the 4th quarter. RA Capital Management L.P. now owns 10,637,290 shares of the company’s stock valued at $147,858,000 after purchasing an additional 220,681 shares during the period. Deutsche Bank AG grew its position in Tyra Biosciences by 52.0% in the 4th quarter. Deutsche Bank AG now owns 18,909 shares of the company’s stock valued at $263,000 after purchasing an additional 6,466 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in Tyra Biosciences in the 4th quarter valued at $761,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on TYRA. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research report on Monday, March 31st. Wedbush reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Friday, March 28th. Finally, Piper Sandler assumed coverage on shares of Tyra Biosciences in a research note on Wednesday, May 21st. They issued an “overweight” rating and a $33.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Tyra Biosciences currently has an average rating of “Buy” and a consensus target price of $30.83.

Tyra Biosciences Price Performance

NASDAQ TYRA opened at $10.55 on Monday. The company has a fifty day moving average price of $9.31 and a 200-day moving average price of $12.12. The firm has a market cap of $560.10 million, a price-to-earnings ratio of -6.55 and a beta of 1.07. Tyra Biosciences, Inc. has a 1 year low of $6.42 and a 1 year high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. On average, research analysts anticipate that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.